iTonic Holdings Ltd Class A Ordinary Shares (ITOC) — Analysis Summary
iTonic Holdings Ltd Class A Ordinary Shares (ITOC) has a market cap of $5.53M with year-over-year revenue growth of +16.7%. Net margin stands at -974.7%. The stock trades at a P/E ratio of -1.1.
Key Takeaways
- Revenue changed +16.7% year-over-year
- Net margin of -974.7%
- P/E ratio of -1.1
Compared with its sector, ITOC posted revenue growth of +16.7% and trades at a P/E of -1.1.
iTonic Holdings Ltd Class A Ordinary Shares (ITOC)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -991.7% — severe operating losses
Net margin at -974.7% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.
Employees
7
Exchange
XNAS
At least 3 years of annual financial data required to assess competitive moat.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.